Price: $11.9
· 1 day: -1.16% · 5 days: +2.23% · 1 month: -17.65% · YTD: +18.33%
As of 2026-11-06 21:00 UTC.
52-week range: $9.54 – $14.62 (currently at 46% of the range).
CTVA is in a downtrend, momentum soft. $12 is the level overhead; $11.79 the first support below.
4 of 6 technical checks lean bearish.
| Trend | Downtrend · below 50-day & below 200-day |
|---|---|
| Momentum | RSI 39.19 · neutral · MACD bearish |
| Trend strength | ADX 18.1 · weak or range |
| Location | -4.8% vs 50-day MA |
| 52-week range | -18% from high · +26% from low |
| Volatility | ATR 0.46 · ~3.9%/day |
| Level | Type | Distance |
|---|---|---|
| $12.0 (resistance) | round | 0.84% |
| $12.12 (resistance) | sma 200 | 1.85% |
| $12.43 (resistance) | swing zone | 4.45% |
| $11.79 (support) | swing zone | -0.92% |
| $11.21 (support) | swing zone | -5.8% |
| $11.0 (support) | round | -7.56% |
| RSI (14) | 39.19 | MACD | -0.2075 |
|---|---|---|---|
| ADX (14) | 18.1 | ATR (14) | 0.46 |
| 50-day average | $12.5 | 200-day average | $12.12 |
Next earnings: 2026-11-11. CTVA earnings date, time and past reactions.
Report of 2026-11-05.
Corteva Inc. has flipped to a bullish stance after reclaiming its 50-day average in late October, with the stock now sitting at $12.59 and leading the S&P 500 by 1.4% over the past 50 days. The five-day gain of nearly 10% contrasts sharply with SPY's 1.1% decline, suggesting the agricultural inputs name has regained relative strength. A close above $13 on above-average volume would trigger a breakout with a 2.5-to-1 reward-to-risk profile targeting the 52-week high at $14.45, though the picture would deteriorate on a weekly close below the 200-day average at $12.12.
The most significant recent development for CTVA is the FTC settlement announced November 1, in which Corteva agreed to pay $35 million to 12 states and accept a ten-year court order restricting post-patent active ingredient practices. This is a material legal outcome that resolves a known uncertainty, though the settlement amount and operational restrictions appear manageable for a company with an $8.4 billion market capitalization. The stock's 9.76% five-day advance suggests the market viewed the resolution as a clean slate rather than a cloud over the business.
The broader agricultural inputs sector is receiving tailwinds from supply disruptions. BASF raised its 2026 adjusted core earnings outlook on October 28, citing demand support from the Iran war and Strait of Hormuz closures. While CTVA operates in a different geography and product mix, the sector's improved tone matters for relative performance and sentiment. The stock's five-day outperformance of SPY by nearly 11 percentage points is not merely a sector story — it reflects CTVA-specific strength, as the stock has gained 25.2% year-to-date against SPY's 11.6%.
The debate on CTVA is split. A November 2 Breakingviews commentary argued that Syngenta's IPO valuation at 15 to 20 times expected 2026 earnings represents an unjustified premium to rivals like Corteva, suggesting the peer comparison may actually flatter CTVA. Meanwhile, the 13 analysts covering the stock maintain a consensus buy with a mean price target of $17.13, implying 26.5% upside from current levels. The analyst spread runs from $13.65 to $20.00, with the low end barely above today's price and the high end suggesting significant upside remains未被 priced in.
The long-term thesis is intact. CTVA trades above its 40-week average, confirming the primary trend remains up, and the stock has gained 25.2% year-to-date against 11.6% for the broader market. The recent pullback from the October 7 peak at $14.45 to the current $12.59 represents a 12.9% decline, but the stock has stabilized and is now attempting to re-establish its uptrend. This is consistent with a healthy correction within an ongoing bull market rather than a trend reversal.
For the next two to six weeks, the balance of evidence leans positive. The daily trend runs with the weekly uptrend, and CTVA is leading the S&P 500 by 1.4% over 50 days. The RSI at 46.05 sits in neutral territory — neither overbought nor oversold — leaving room for further upside. The stance changed from bearish to bullish because price closed above the 50-day average at 12.52 on October 27, 2026, which was the invalidation level for the prior bearish view. Medium conviction reflects two of four positive factors: the trend alignment and relative strength versus the market. Against this reading, the stock is still down 9.5% over the past month, and volume over the past 20 days has been extremely light at 95.7% below average — a sign of distribution or lack of conviction. Those concerns do not tip the balance because the structural reclaim of the 50-day average is a meaningful technical shift, and the near-term catalyst of earnings on November 11 could provide the next catalyst.
The structure holds above the 50-day average at $12.52, which is the first crack below. If price loses that level, the next support sits at the 200-day average at $12.12, where the weekly trend would end. Below $12.12, the bullish thesis would be in question. The 52-week low at $9.47 is distant but represents the lower bound of the current range.
The breakout level is $13.0 on a daily close with volume above the 20-day average. From there, the math gives a target of $14.45 based on the 52-week high, with a stop at $12.41 (the 50-day average minus a quarter of the 14-day ATR of $0.44). That produces a reward-to-risk ratio of 2.5 to 1, meeting the 3-to-1 threshold. A second target at $74.47 exists but is a swing zone rather than a near-term objective and carries a 104-to-1 ratio that reflects the distance from current levels. The near-term trade is the $14.45 level.
A weekly close below the 200-day average at $12.12 would shift the outlook. That is the level and rule specified for a picture change. Beyond price, the November 11 earnings report is the non-price event that could redefine the thesis — the number to watch there is whether management raises, maintains or cuts full-year guidance in light of the FTC settlement and the sector dynamics highlighted by BASF's outlook improvement.
Interactive CTVA chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs